Percent response to FCC by disease characteristics
| Patient characteristics (N = 43) . | n . | NCI-WG response, n (%) . | |||
|---|---|---|---|---|---|
| CR (all patients) . | CR (MRD−) . | PR . | ORR . | ||
| All patients | 43 | 13 (30) | 6 (14) | 16 (37) | 29 (67) |
| Binet | |||||
| A | 1 | 0 | 0 | 1 (100) | 1 (100) |
| B | 24 | 10 (42) | 4 (17) | 6 (25) | 16 (67) |
| C | 18 | 3 (17) | 2 (11) | 9 (50) | 12 (67) |
| Disease status | |||||
| Relapse | 32 | 10 (31) | 5 (16) | 12 (38) | 22 (69) |
| Resistant | 11 | 3 (27) | 1 (9) | 4 (36) | 7 (63) |
| No. of previous treatments | |||||
| 1 | 10 | 5 (50) | 1 (10) | 5 (50) | 10 (100)† |
| 2 | 20 | 6 (30) | 4 (20) | 8 (40) | 14 (70) |
| ≥ 3 | 13 | 2 (15) | 1 (8) | 3 (23) | 5 (38) |
| Previous fludarabine | |||||
| Yes | 40 | 11 (28) | 6 (15) | 15 (37) | 26 (65) |
| No | 3 | 2 (67) | 0 | 1 (33) | 3 (100) |
| Previous alkylating agent | |||||
| Yes | 38 | 10 (26) | 5 (13) | 14 (37) | 24 (63) |
| No | 5 | 3 (60) | 1 (20) | 2 (40) | 5 (100) |
| Previous anthracycline | |||||
| Yes | 9 | 3 (33) | 1 (11) | 2 (22) | 5 (55) |
| No | 34 | 10 (29) | 5 (15) | 14 (41) | 24 (70) |
| Previous monoclonal antibody | |||||
| Yes | 16 | 2 (13) | 2 (13) | 4 (25) | 6 (38)‡ |
| No | 27 | 11 (41) | 4 (15) | 12 (44) | 23 (85) |
| Fludarabine refractory* | |||||
| Yes | 6 | 1 (17) | 0 | 3 (50) | 4 (67) |
| No | 34 | 10 (29) | 6 (18) | 12 (35) | 22 (65) |
| IgVH status* | |||||
| Mutated | 11 | 6 (55) | 3 (27) | 2 (18) | 8 (73) |
| Unmutated | 23 | 5 (22) | 3 (13) | 13 (57) | 18 (79) |
| ZAP70* | |||||
| Negative | 16 | 5 (31) | 2 (13) | 5 (31) | 10 (62) |
| Positive | 17 | 5 (29) | 3 (18) | 8 (47) | 13 (76) |
| FISH* | |||||
| Normal or 13q deletion | 15 | 6 (40) | 4 (27) | 6 (40) | 12 (80) |
| Trisomy 12 | 6 | 3 (50) | 0 | 1 (17) | 4 (67) |
| 11q deletion | 7 | 1 (14) | 0 | 3 (43) | 4 (57) |
| 17p deletion | 11 | 3 (27) | 2 (18) | 5 (46) | 8 (73) |
| Patient characteristics (N = 43) . | n . | NCI-WG response, n (%) . | |||
|---|---|---|---|---|---|
| CR (all patients) . | CR (MRD−) . | PR . | ORR . | ||
| All patients | 43 | 13 (30) | 6 (14) | 16 (37) | 29 (67) |
| Binet | |||||
| A | 1 | 0 | 0 | 1 (100) | 1 (100) |
| B | 24 | 10 (42) | 4 (17) | 6 (25) | 16 (67) |
| C | 18 | 3 (17) | 2 (11) | 9 (50) | 12 (67) |
| Disease status | |||||
| Relapse | 32 | 10 (31) | 5 (16) | 12 (38) | 22 (69) |
| Resistant | 11 | 3 (27) | 1 (9) | 4 (36) | 7 (63) |
| No. of previous treatments | |||||
| 1 | 10 | 5 (50) | 1 (10) | 5 (50) | 10 (100)† |
| 2 | 20 | 6 (30) | 4 (20) | 8 (40) | 14 (70) |
| ≥ 3 | 13 | 2 (15) | 1 (8) | 3 (23) | 5 (38) |
| Previous fludarabine | |||||
| Yes | 40 | 11 (28) | 6 (15) | 15 (37) | 26 (65) |
| No | 3 | 2 (67) | 0 | 1 (33) | 3 (100) |
| Previous alkylating agent | |||||
| Yes | 38 | 10 (26) | 5 (13) | 14 (37) | 24 (63) |
| No | 5 | 3 (60) | 1 (20) | 2 (40) | 5 (100) |
| Previous anthracycline | |||||
| Yes | 9 | 3 (33) | 1 (11) | 2 (22) | 5 (55) |
| No | 34 | 10 (29) | 5 (15) | 14 (41) | 24 (70) |
| Previous monoclonal antibody | |||||
| Yes | 16 | 2 (13) | 2 (13) | 4 (25) | 6 (38)‡ |
| No | 27 | 11 (41) | 4 (15) | 12 (44) | 23 (85) |
| Fludarabine refractory* | |||||
| Yes | 6 | 1 (17) | 0 | 3 (50) | 4 (67) |
| No | 34 | 10 (29) | 6 (18) | 12 (35) | 22 (65) |
| IgVH status* | |||||
| Mutated | 11 | 6 (55) | 3 (27) | 2 (18) | 8 (73) |
| Unmutated | 23 | 5 (22) | 3 (13) | 13 (57) | 18 (79) |
| ZAP70* | |||||
| Negative | 16 | 5 (31) | 2 (13) | 5 (31) | 10 (62) |
| Positive | 17 | 5 (29) | 3 (18) | 8 (47) | 13 (76) |
| FISH* | |||||
| Normal or 13q deletion | 15 | 6 (40) | 4 (27) | 6 (40) | 12 (80) |
| Trisomy 12 | 6 | 3 (50) | 0 | 1 (17) | 4 (67) |
| 11q deletion | 7 | 1 (14) | 0 | 3 (43) | 4 (57) |
| 17p deletion | 11 | 3 (27) | 2 (18) | 5 (46) | 8 (73) |
FCC indicates fludarabine, cyclophosphamide, alemtuzumab; NCI-WG, National Cancer Institute Working Group; CR, complete response; PR, partial response; and ORR, overall response rate.
Data not available in all patients.
Statistically significant difference between patients treated with one prior line of therapy versus those treated with > 1 prior line of therapy (P < .05).
Statistically significant difference between patients treated with monoclonal antibodies versus no monoclonal antibodies (P < .05).